Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Bridge Biotherapeutics Inc (288330)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2,190 +15    +0.69%
03/05 - Closed. Currency in KRW ( Disclaimer )
  • Volume: 516,314
  • Bid/Ask: 2,190 / 2,195
  • Day's Range: 2,130 - 2,335
Type:  Equity
Market:  South Korea
ISIN:  KR7288330004 
Bridge Bio 2,190 +15 +0.69%

Bridge Biotherapeutics Inc Company Profile

 
Get an in-depth profile of Bridge Biotherapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

43

Equity Type

ORD

Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was founded in 2015 and is headquartered in Seongnam, Korea.

Contact Information

Address Building B, Innovalley Suite 903-2
253 Pangyo-ro Bundang-gu Seongnam, 13486
South Korea
Phone -
Fax -

Top Executives

Name Age Since Title
James Jungkue Lee - - CEO & Director
Seoungyeob Paek - - Independent Outside Director
SeungHoon Lee - - Independent Outside Director
Yul Yoo Choo - - Independent Outside Director
B. Christopher Kim - 2021 Executive VP & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

288330 Comments

Write your thoughts about Bridge Biotherapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email